Promising Pancreatic Cancer Data
from OncoPharm Hosted by John Bossaer
This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has shown OS benefit vs. chemo in the 2nd-line setting of metastatic pancreatic cancer compared to investigator's choice chemotherapy. Hopefully, we will get the abstract soon and publication shortly thereafter. A personalized mRNA vaccine for early-stage pancreatic cancer has some encouraging results (for those patients who mounted a sizable immune response to the vaccine). Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
Embed this episode
No transcript yet.